Extracellular vesicles: A new therapeutic strategy for joint conditions

[EN] Extracellular vesicles (EVs) are attracting increasing interest since they might represent a more convenient therapeutic tool with respect to their cells of origin. In the last years much time and effort have been expended to determine the biological properties of EVs from mesenchymal stem cells (MSCs) and other sources. The immunoregulatory, anti-inflammatory and regenerative properties of MSC EVs have been demonstrated in in vitro studies and animal models of rheumatoid arthritis or osteoarthritis. This cell-free approach has been proposed as a possible better alternative to MSC therapy in autoimmune conditions and tissue regeneration. In addition, EVs show great potential as biomarkers of disease or delivery systems for active molecules. The standardization of isolation and characterization methods is a key step for the development of EV research. A better understanding of EV mechanisms of action and efficacy is required to establish the potential therapeutic applications of this new approach in joint conditions. This work has been funded by grants SAF2013-48724R (MINECO,FEDER, Spain) and PROMETEOII/2014/071 (Generalitat Valenciana, Spain). Tofiño-Vian, M.; Guillen Salazar, MI.; Alcaraz Tormo, MJ. (2018). Extracellular vesicles: A new therapeutic strategy for joint conditions. Biochemical Pharmacology. 153:134-146. https://doi.org/10.1016/j.bcp.2018.02.004